Global Azilsartan Medoxomil API Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030

Global Azilsartan Medoxomil API Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030

Azilsartan medoxomil (trade name Edarb) is an angiotensin II receptor blocker (ARB) that lowers blood pressure by blocking the action of angiotensin II, a vasopressor hormone. It is indicated for the treatment of hypertension to lower blood pressure which reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. Azilsartan medoxomil may be used either alone or in combination with other antihypertensive agents such as chlorthalidone (CLD). As an ARB, azilsartan medoxomil selectively inhibits angiotensin II from binding to the angiotensin II type-1 receptor (AT1). This receptor inhibition provides the antihypertensive activity of azilsartan medoxomil because it blocks the pressor effects of angiotensin II. Azilsartan medoxomil is a prodrug of azilsartan. It is hydrolyzed to the active moiety, azilsartan, in the gastrointestinal (GI) tract during the absorption phase.

According to our (Global Info Research) latest study, the global Azilsartan Medoxomil API market size was valued at US$ 19.2 million in 2023 and is forecast to a readjusted size of USD 66 million by 2030 with a CAGR of 19.5% during review period.

Main manufacturers of global azilsartan medoxomil API market are Takeda, Metrochem API and Jubilant Pharma. Takeda and Metrochem API are the top 2 players and accounts for over 40% of global market share in total. Geographically speaking, USA is the largest market and covers about 30% of total market share, followed by Europe with 20%. In terms of application, 40 mg Tablets holds an important market share of over 50%.

This report is a detailed and comprehensive analysis for global Azilsartan Medoxomil API market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2024, are provided.

Key Features:

Global Azilsartan Medoxomil API market size and forecasts, in consumption value ($ Million), sales quantity (Kg), and average selling prices (USD/Kg), 2019-2030

Global Azilsartan Medoxomil API market size and forecasts by region and country, in consumption value ($ Million), sales quantity (Kg), and average selling prices (USD/Kg), 2019-2030

Global Azilsartan Medoxomil API market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (Kg), and average selling prices (USD/Kg), 2019-2030

Global Azilsartan Medoxomil API market shares of main players, shipments in revenue ($ Million), sales quantity (Kg), and ASP (USD/Kg), 2019-2024

The Primary Objectives in This Report Are:

To determine the size of the total market opportunity of global and key countries

To assess the growth potential for Azilsartan Medoxomil API

To forecast future growth in each product and end-use market

To assess competitive factors affecting the marketplace

This report profiles key players in the global Azilsartan Medoxomil API market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Takeda, Lupin, Acura Labs, Metrochem API, Jubilant Pharma, Zhejiang Hongyuan, Honour Lab, HEC Pharm, Enomark, CTX Life Sciences, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Market Segmentation

Azilsartan Medoxomil API market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type
0.99
Others

Market segment by Application
20 mg Tablets
40 mg Tablets
80 mg Tablets

Major players covered
Takeda
Lupin
Acura Labs
Metrochem API
Jubilant Pharma
Zhejiang Hongyuan
Honour Lab
HEC Pharm
Enomark
CTX Life Sciences
Zhejiang Tianyu
Zhuhai Rundu
Valiant Co

Market segment by region, regional analysis covers

North America (United States, Canada, and Mexico)

Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)

Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)

South America (Brazil, Argentina, Colombia, and Rest of South America)

Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)

The content of the study subjects, includes a total of 15 chapters:

Chapter 1, to describe Azilsartan Medoxomil API product scope, market overview, market estimation caveats and base year.

Chapter 2, to profile the top manufacturers of Azilsartan Medoxomil API, with price, sales quantity, revenue, and global market share of Azilsartan Medoxomil API from 2019 to 2024.

Chapter 3, the Azilsartan Medoxomil API competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the Azilsartan Medoxomil API breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2019 to 2030.

Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2019 to 2030.

Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2019 to 2024.and Azilsartan Medoxomil API market forecast, by regions, by Type, and by Application, with sales and revenue, from 2025 to 2030.

Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.

Chapter 13, the key raw materials and key suppliers, and industry chain of Azilsartan Medoxomil API.

Chapter 14 and 15, to describe Azilsartan Medoxomil API sales channel, distributors, customers, research findings and conclusion.